Sydney Adventist Hospital 02 9487 9111

Sydney Adventist Hospital
« View pages

Clinical Specialties

Prostate Cancer Clinical Trials


Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Metastatic Prostate Cancer Who Have Failed on Androgen Deprivation Therapy and Have Not Received Previous Chemotherapy

Mic-1 - Recruiting

Phase II Study to Investigate the Ability of Macrophage Inhibitory Cytokine-1 (MIC-1)


A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer


A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.


Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer

Enzarad – Recruiting

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer


A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer (SPARTAN)


A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Embark – Recruiting

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With HighRisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

Keynote 199 – Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199)

Galahad – Recruiting

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)

HERO – Recruiting

A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer

Back to Top

Sydney Adventist Hospital Clinical Specialties and Services